Published in Cancer Weekly, August 8th, 2006
The grant will be provided over two years under the Australian Government's Commercial Ready program, a competitive merit-based grant program supporting innovative product research and development.
DMF10 is a hamster antibody which has shown strong evidence of activity against lung cancer and melanoma. The antibody attacks a structure on the surface of cancer cells that is not found on normal cells, creating a cancer therapy that is potentially both effective and devoid of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.